Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria

By Reuters News12:54 (UTC), 22 September 2026 Updated

Sept 22 (Reuters) - Vertex Pharmaceuticals Incorporated VRTX.O:

VERTEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2B AMPLIFIED STUDY OF INAXAPLIN IN ADDITIONAL POPULATIONS OF PEOPLE WITH APOL1-MEDIATED KIDNEY DISEASE (AMKD) AND COMPLETION OF ENROLLMENT IN THE PHASE 2/3 AMPLITUDE TRIAL
VERTEX PHARMACEUTICALS INCORPORATED - INAXAPLIN REDUCES UACR BY -42.7% AT WEEK 13 IN AMKD WITH MODEST PROTEINURIA
VERTEX PHARMACEUTICALS INCORPORATED - INAXAPLIN REDUCES UACR BY -17.3% AT WEEK 13 IN AMKD WITH TYPE 2 DIABETES
VERTEX PHARMACEUTICALS INCORPORATED - INAXAPLIN GENERALLY SAFE AND WELL TOLERATED IN BOTH AMKD COHORTS

Further company coverage: VRTX.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.